Objetivo
Describir el tipo de relación entre el médico de familia de atención primaria (MAP) y la industria farmacéutica (IF) y sus representantes en Aragón, describir las actitudes del médico hacia dicha relación y conocer la conducta del médico ante las ofertas de la industria
Diseño
Estudio descriptivo transversal mediante cuestionario aplicable de respuestas cerradas a una muestra representativa de la población de estudio
Ámbito Y Sujetos De Estudio
Médicos de familia que trabajan en equipos de atención primaria de todo el territorio de Aragón
Resultados
La tasa de respuesta fue de un 28,17%, manteniéndose la representatividad. En cuanto al tipo de relación entre el MAP y la IF, hay diferencias según el sexo (con una mayor relación de los varones) y el medio (mayor en el medio urbano). La actitud es más crítica entre los médicos que trabajan en centros con acreditación docente y entre las mujeres profesionales. La tendencia a colaborar con las ofertas de la industria es mayor en el medio rural y entre los varones. El grupo de médicos con mayor interacción con la industria tiende a colaborar más con las propuestas de la IF. No se ha encontrado. relación entre la actitud y la conducta de los MAP
Conclusiones
Los resultados confirman las hipótesis de partida: a) el estilo de relación entre el MAP y la IF y sus representantes infuye en la conducta prescriptora, y b) hay deferencias entre lo que el profesional considera que debe hacerse y lo que se hace realmente en sus relaciones con la IF
Palabras clave: Ética, Industria farmacéutica, Médico de atención primaria
Abstract
Objectives
To describe the type of relationship between primary care family doctors (PCDs) and the pharmaceutical industry (PI) and its representatives in Aragon, to describe doctors' attitudes to this relationship and to find out how doctors behave towards offers from the industry
Design
Descriptive cross-sectional study, through a self-filled questionnaire with closed replies, of a representative sample of the population under study
Setting And Participants
Family doctors working in primary care teams throughout Aragon
Results
The reply rate of 28.17% maintained the study's representativity. Differences in the kind of relationship between PCDs and PI were found in gender (greater relationship of male doctors) and setting (it was greater in urban areas). Doctors working in centres with teaching credentials and woman doctors had a more critical attitude. The tendency to collaborate with the industry's offers was greater in the rural areas and among men. The group of doctors that interacted most with the industry tended to collaborate more with the proposals of the PI. No relationship was found between attitude and conduct of PCDs
Conclusions
Results confirm both the starting hypotheses: a) the nature of relationships between PCDs and the PI and its representatives affects prescribing behaviour, and b) there are differences between what doctors think they should do and what they really do in their dealings with the PI
Keywords: Ethics, Pharmaceutical industry, Primary Care doctor
Esta investigación ha recibido financiación del Fondo de Investigación Sanitaria del Ministerio de Sanidad y Consumo (expediente FIS n.° P1021087)
Bibliografía
- 1.Declaración de Lisboa Derechos del paciente. Adoptada por la 34.a Asamblea Médica Mundial (Lisboa, septiembre-octubre de 1981) Bol Sanit Panam. 1990;108(5-6):642. [Google Scholar]
- 2.Declaración de la Comisión Central de Deontología sobre Ética de la Prescripción. OMC; Madrid: 1988. [Google Scholar]
- 3.Galán Herrera S., Delgado Marroquín M.T., Altisent Trota R. Elaboración de un cuestionario para el estudio de la relación entre el médico y la industria farmacéutica. Aten Primaria. 2004;34:87–91. doi: 10.1016/S0212-6567(04)79465-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Sergeant M.D., Hodgetts P.G., Godwin M., Walker D., McHenry P. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. Can Med Assoc J. 1996;155:1243–1259. [PMC free article] [PubMed] [Google Scholar]
- 5.Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. Can Med Assoc J. 1995;153:553–559. [PMC free article] [PubMed] [Google Scholar]
- 6.Reeder M., Dougherty J., White L. Pharmaceutical representatives and emergency medicine residents: a national survey. Ann Emerg Med. 1993;22:1593–1596. doi: 10.1016/s0196-0644(05)81266-1. [DOI] [PubMed] [Google Scholar]
- 7.Keim S., Sanders A., Witzke D., Dyne P., Fulginiti J. Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. Ann Emerg Med. 1993;22:1576–1581. doi: 10.1016/s0196-0644(05)81262-4. [DOI] [PubMed] [Google Scholar]
- 8.Lichstein P., Turner R., O'Brien K. Impact of pharmaceutical company representatives on internal medicine residency programs. A survey of residency program directors. Arch Intern Med. 1992;152:1009–1013. [PubMed] [Google Scholar]
- 9.Brotzman G., Mark D. Policies regulating the activities of pharmaceutical representatives in residency programs. J Fam Pract. 1992;34:54–57. [PubMed] [Google Scholar]
- 10.Lurie N., Rich E., Simpson D., Meyer J., Schiedrmayer D., Goodman J. Pharmaceutical representatives in academic medical centers. J Gen Intern Med. 1990;5:240–243. doi: 10.1007/BF02600542. [DOI] [PubMed] [Google Scholar]
- 11.Strang D., Gagnon M., Mohillo W., Bédard M., Darzins P., Etchells E. National survey on the attitudes of Canadian Physicians towards drug-detailing by pharmaceutical representatives. Ann R Coll Physicians Surg Can. 1996;29:474–478. [PubMed] [Google Scholar]
- 12.Poirier T., Giannetti V., Giudici R. Pharmacists' and physicians' attitudes toward pharmaceutical marketing practices. Am J Hosp Pharm. 1994;51:378–381. [PubMed] [Google Scholar]
- 13.Caudill T.S., Johnson M.S., Rich E.C., McKinney P. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996;5:201–206. doi: 10.1001/archfami.5.4.201. [DOI] [PubMed] [Google Scholar]
- 14.Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? Jama. 2000;283:373–380. doi: 10.1001/jama.283.3.373. [DOI] [PubMed] [Google Scholar]
- 15.Banks III J., Manious III A. Attitudes of medical school faculty toward gifts from the pharmaceutical industry. Acad Med. 1992;67:610–612. doi: 10.1097/00001888-199209000-00017. [DOI] [PubMed] [Google Scholar]
- 16.Thompson A.N., Craig B.J., Barham P.M. Attitudes of general practicioners in New Zealand to pharmaceutical representatives. Br J Gen Pract. 1994;44:220–223. [PMC free article] [PubMed] [Google Scholar]
- 17.Chren M.M., Landefeld C.S. Physicians' behavior and their interactions with drug companies. Jama. 1994;271:684–689. [PubMed] [Google Scholar]
- 18.Orlowsky J.P., Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest. 1992;102:270–273. doi: 10.1378/chest.102.1.270. [DOI] [PubMed] [Google Scholar]
- 19.Spingarn R.W., Berlin J.A., Strom B.L. When pharmaceutical manufacturerers'employers present grand rounds, what do residents remember? Acad Med. 1996;71:86–88. doi: 10.1097/00001888-199601000-00022. [DOI] [PubMed] [Google Scholar]
- 20.Abbasi K., Smith R. No more free lunch. Bmj. 2003;326:1155–1156. doi: 10.1136/bmj.326.7400.1155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. Bmj. 2003;326:1189–1192. doi: 10.1136/bmj.326.7400.1189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. Bmj. 2003;326:1193–1196. doi: 10.1136/bmj.326.7400.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Wager E. How to dance with porcupines: rules and guidelines on doctors' relations with drug companies. Bmj. 2003;326:1196–1198. doi: 10.1136/bmj.326.7400.1196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Altisent R. IV Congreso Nacional de la Sociedad de Bioética Fundamental y Clínica. Bilbao; 2-4 de noviembre de 2000. Problemas éticos en la práctica diaria: de la investigación a la prescripción. [Google Scholar]